EAU22 BCa highlights

The just concluded EAU Annual Congress 2022 was held from 1-4 July in Amsterdam. Here are the BCa highlights and vital findings presented at this annual meeting.

Key lectures:

• Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomised clinical trial
• Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010
• Debate: NMIBC BCG refractory tumour – What are the systemic options in the pipeline?
• State-of-the-art lecture: Landscape of current trials with intravesical treatment in high risk BCG naïve NMIBC
• State-of-the-art lecture: Molecular classification in bladder cancer to guide systemic treatment: ready from prime time?

Interviews with KOL’s:

• Prof. Catto on Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomised clinical trial
• Prof. Gschwend on IMvigor010 trial

Abstracts:

• Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment
• [18F]-FDG PET/CT for bladder cancer staging and decision-making in patients with High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)